[email protected]
David Fiellin
Professor of Medicine, of Emergency Medicine, and of Public Health; Director, Yale Program in Addiction Medicine
Dr. David Fiellin has focused his scholarly work on the interface between primary care, HIV and addiction. He is a primary care internist Board Certified in Internal Medicine and Addiction Medicine. He serves as the inaugural Director of the Yale Program in Addiction Medicine. He conducts research on the transfer of treatment strategies, including opioid agonist maintenance with methadone and buprenorphine, from specialized settings to office-based, primary care, Emergency Department and HIV specialty settings. He has served as Principal Investigator on multiple NIH-funded trials and directed the SAMHSA Physician Clinical Support System for buprenorphine. He is the Director of the Community Research and Implementation Core at Yale's Center for Interdisciplinary Research on AIDS. He has received awards including the Nyswander/Dole Award from the American Association for the Treatment of Opioid Dependence, the 2008 Annual Award from the American Society of Addiction Medicine, the Excellence in Mentorship Award from AMERSA and the Dan Anderson Research Award from the Hazelden-Betty Ford Foundation. He has served on the White House Office of National Drug Control Policy (ONDCP), Drug Control Research, Data, and Evaluation Advisory Committee, and the World Health Organization and United Nations Office on Drugs and Crime Technical Guideline Development Group for psychosocially assisted pharmacologic treatment of opioid dependence. He served as Chair of the Center for Substance Abuse Treatment's, Treatment Improvement Protocol on Treatment of Viral Hepatitis in Patients with Substance Use Disorders and on the Editorial Boards of Substance Abuse and the Journal of Addiction Medicine and is Co-Editor of Alcohol, Other Drugs & Health: Current Evidence and the Principles of Addiction Medicine, 4th, 5th and 6th Edition. He has served on the Board of Directors of the College on Problems of Drug Dependence and as Co-Chair of the Substance Abuse Task Force for the Society of General Internal Medicine.
News
Related Speakers View all
Brandon David Lewis Marshall
Associate Professor of Epidemiology at Brown University
|
|
Kathryn Hawk
Assistant Professor of Emergency Medicine at Yale Un...
|
|
Wilson Compton
Deputy Director of the National Institute on Drug Ab...
|
|
John Kelly, PhD
Professor of Psychiatry in Addiction Medicine at Har...
|
|
Anna Lembke
Chief of the Stanford Addiction Medicine Dual Diagno...
|
|
Chris Johnson, MD
Physician, Expert Speaker on the Opioid Crisis, Foun...
|
|
W. Michael Hooten
Mayo Clinic Anesthesiologist & Pain Specialist
|
|
Jonathan Perlin
President & CEO of The Joint Commission, Leading Hea...
|
|
Dr. Rochelle Walensky
Nominee for Director of the CDC in the Biden Adminis...
|
|
Daniel Buccino
Clinical Manager at the Johns Hopkins Broadway Cente...
|
|
Aaron Weiner
Psychologist & Owner of Bridge Forward Group
|
|
Harold K. Tu
Director of the Division of Oral and Maxillofacial S...
|
|
Natalie Kirilichin
Emergency Physician and Health Policy Fellow
|
|
Ezekiel Fink
Chief Medical Officer at Cedar Health Research
|
|
Dr. Alaa Abd-Elsayed
University of Wisconsin Pain Services Doctor
|
|
Kelly Clark
Founder and President of Addiction Crisis Solutions
|
|
Suchitra Krishnan-Sarin
Professor of Psychiatry at the Yale University Schoo...
|
|
Daniel Ciccarone
Professor of Family & Community Medicine at UCSF Med...
|
|
Jerome M. Adams
20th U.S. Surgeon General & Vice Admiral of the U.S....
|
|
Adi Jaffe, Ph.D.
Mental Health & Addiction Specialist
|